Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Substance Regulation topic
No spam. Unsubscribe anytime.
Clinic owner urges Northfield to ban concentrated '7‑OH' products over youth access and public‑health concerns
Summary
Phil Adterbury, owner of Bright Side addiction recovery clinic, asked trustees to direct staff to draft an ordinance banning retail sales of concentrated 7‑hydroxy‑mitragynine, citing increased clinic visits, easy youth access at convenience stores, unclear labeling and opioid‑like effects.
At the March 24 village board meeting, Phil Adterbury, who identified himself as the owner of Bright Side addiction recovery clinic, urged trustees to consider an ordinance banning retail sales of concentrated 7‑hydroxy‑mitragynine products (referred to in the meeting as "7‑OH").
Adterbury said his clinic has seen a substantial increase in clients and that concentrated formulations of the alkaloid — sold in gas stations, smoke shops and other retail outlets — are engineered for stronger, faster effects and marketed in packaging attractive to young people. "This isn't the same as traditional kratom leaf," he said, arguing that concentrated products have opioid‑like properties and present risks of dependence, adverse reactions and dangerous interactions with other substances.
He asked the board to direct staff to draft an ordinance banning retail sale of concentrated 7‑OH formulations in Northfield and to return the proposal for discussion and a public hearing. He said similar bans have been enacted elsewhere, noting a neighboring community had already banned the product.
Trustees did not take formal action on the request during the meeting; the item remained a public comment and was not listed on the agenda for immediate staff direction.
